Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement, page-414

OriginallypostedbyQuanta

Technicallyonly97missuedcapitalandtop20with37%leavingasmallfreefloat.ThereisonlysomuchCDYcanchurnintradaybeforemovinginnortherlydirectionsignificantlytoday.Hugebiddingvolumescomingthroughonthebuyside.Surelythisisbeingbeingaccumulatedbythebroadermarket.

Alsothereissignificantcommercialnewsinthepipelineandstepsforwad.TheCovidtestkitthatCDYhasanagreementforhasonlybeenapprovedbytheTGAonthe25thanditisoneofthefirstonmarketinAustralia.UnsurehowMariamanagedtosecurethisdealhoweversheshouldbetryingtosellthecovidtestthroughCDYsglobaldistributionchannelsandmarketsifthemanufacturerallowsthis.

Hi Quanta

There are fundamental reasons as to why long term holders stick to this stock like glue.

Proper research the company and its pipelines to maybe needed to understand why but to cut a long story short the midkine antibody pipeline is worth billions to big pharma.

The planned separation of Lyramid would (on the basis of similar sector transactions) be expected to raise a lot of cash and a valuable royalty. That transaction would allow the company to action its other midkine pipeline which focuses on stuff like cardiac infarction.

cheers